Searching for Solutions

No summary available

Eliminate confusion about the use of buprenorphine and methadone in acute care settings by accessing an FAQ resource addressing the most common questions and scenarios.

Sold as a readily available supplement, phenibut is not approved for medical use in the U.S. It has a high potential for abuse and dependency making AAPP’s newest toolkit an important read. Author Sarah Thomason addresses phenibut’s mechanism of misuse, clinical presentation, and management of acute intoxication and withdrawal among other topics. Check out this timely member resource today.

Despite their importance as first-line options for OUD treatment, confusion remains regarding their use in acute care settings, especially when patients seek care at institutions that do not have opioid treatment program (OTP) licensure. AAPP members and authors Zoe Karovolis, Emily Leppien, and Annette Percy have developed a go-to resource addressing frequently asked questions regarding the use of buprenorphine and methadone in acute care settings.

Learn skills to effectively manage meetings during this 3-part, live virtual workshop! This exclusive workshop is limited to just 20 learners, and the first session is Sept. 9. Register now to secure your spot!

In this JAMA Pediatrics article presenting the results of a nationally representative survey study of US adolescents and young adults, a fifth reported using AI chatbots for mental health advice.

This report examines data from the Centers for Disease Control and Prevention (CDC) and other federal sources.

This study of Medicaid records from 29,193 women found that pregnant women who received OUD treatment, including medication, talk-based therapies, or both, had significantly better pregnancy outcomes than those who received no treatment.

The 2026 AAPP Outcomes Research Grants provide $15,000 each to support retrospective studies on bipolar, clozapine, and MOUD. Mark your calendar for the Q&A session June 30, 2026! Get your questions answered and learn how to advance your research. #PsychPharm

The CURESZ Foundation (Comprehensive Understanding via Research and Education into SchiZophrenia) founded by Bethany Yeiser and Dr. Henry Nasarallah has assembled a Clozapine in Schizophrenia Expert Panel (CLOSZE). The goal is to assist individuals living with schizophrenia and/or caregivers in finding a clinician who can assist them in trying clozapine. AAPP encourages psychiatric pharmacists to sign up for the registry so that patients/caregivers can outreach to establish ongoing care.

No summary available

Practice, practice, practice! The 150-question mock exam lets you test your knowledge, pacing, and endurance before sitting for the BCPP certification exam. #BCPP #AAPP #examprep #psychpharmacy

Learn all about Antipsychotic Long-Acting Injectable Pharmacology and Dosing in this module! This is one of six modules in our complimentary Psychotropic LAI Training Program. Register today and get access to the full program and LAI resources.